CERTIFICATION EXAM AND
PRACTICE PREP CARDIOVASCULAR
QUESTIONS & ANSWERS UPDATED
2026
YouBexamineBaB38ByearBoldBwomanBwhoBhasBpresentedBforBanBinitialBexaminationBan
dBPapanicolaouBtest.BSheBhasBnoBcomplaint.BHerBBPBisB154/98BmmBHgBbilaterallyBand
BherBBMIBisB31Bkg/m2.BTheBrestBofBherBphysicalBexamBisBunremarkable.BYourBnextBbe
stBactionBisBto:
A.BinitiateBantihypertensiveBtherapy
B.BarrangeBforBatBleastBtwoBadditionalBBPBmeasurementsBduringBtheBnextB2Bweeks.
C.BorderBBUN,Bcreatinine,BandBpotassiumBionBmeasurementsBandBUA
D.BadviseBherBtoBreduceBherBsodiumBintakeB-
BAnswerB.BarrangeBforBatBleastBtwoBadditionalBBPBmeasurementsBduringBtheBnextB2Bw
eeks
YouBseeBaB68ByearBoldBwomanBasBaBptBwhoBisBtransferringBcareBintoByourBpractice.BS
heBhasBaB10yBhistoryBofBHTN,BdiabetesBmellitus,BandBhyperlipidemia.BCurrentBmedicati
onsBincludeBHCTZ,Bglipizide,Bmetformin,Bsimvastatin,BandBdailyBlow-
doseBaspirin.BToday'sBBPBreadingBisB158/92mmBHgBandBtheBrestBofBherBhistoryBandBe
xamBareBunremarkable.BDocumentationBfromBherBformerBhealthcareBproviderBindicates
BthatBherBBPBhasBbeenBinBtheBrangeBforBtheBpastB12Bmonths.BYourBnextBbestBactionBi
sBto:B
A.BprescribeBanBACEI
B.BhaveBherBreturnBforBaBBPBcheckBinB1Bweek
C.BadviseBthatBherBcurrentBtherapyBisBadequate
D.BaddBtherapyBwithBanBaldosteroneBantagonistB-BAnswerA.BprescribeBanBACEI
YouBexamineBaB78By/oBwomanBwithBlong-
standingBpoorlyBcontrolledBhHTN.BWhenBevaluatingBherBforBHTNBtargetBorganBdamage,
ByouBlookBforBevidenceBof:
A.BlipidBabnormalities
,B.BinsulinBresistance
C.BleftBventricularBhypertrophy
D.BclottingBdisordersB-BAnswerC.BleftBventricularBhypertrophy
DiagnosticBtestingBforBaBptBwithBnewlyBdiagnosedBprimaryBhHTNBshouldBincludeBallBof
BtheBfollowingBexcept:
A.Bhematocrit
B.BuricBacid
C.Bcreatinine
D.BpotassiumB-BAnswerB.BuricBacid
InBtheBpersonBw/HTN,BtheBnurseBpractitionerBrecommendsBallBofBtheBfollowingBtoBpot
entiallyBreduceBBPBinBaBpatientBwithBaBBMIBofB30Bkg/m2Bexcept:
A.B10kgBweightBloss
B.BdietaryBsodiumBrestrictionBtoB2.4gBperBday
C.BregularBaerobicBphysicalBactivity,BsuchBasB30-
40BminutesBofBbriskBwalkingBmostBdaysBofBtheBweek
D.BconsumingBatBleastB1-2BservingsBofBalcoholB-BAnswerD.BconsumingBatBleastB1-
2BservingsBofBalcohol
whatBclassBofBantihypertensionBmedicationBisBamlodipine?B-
BAnswerdihydropyridineBcalciumBchannelBblocker
whatBclassBofBantihypertensionBmedicationBisBdiltiazem?B-
BAnswernondihydropyridineBcalciumBchannelBblocker
whatBclassBofBantihypertensionBmedicationBisBtrandolapril?B-BAnswerACEI
whatBclassBofBantihypertensionBmedicationBisBtelmisartan?B-
BAnswerangiotensinBreceptorBantagonist
, whatBclassBofBantihypertensionBmedicationBisBpindolol?B-BAnswerbeta-
adrenergicBreceptorBantagonist
YouBseeBaB38-
yearBoldBAfricanBAmericanBmaleBwithBHTNBwhoBisBcurrentlyBbeingBtreatedBwithBthiazi
de-
typeBdiuretic.BHisBcurrentBBPBreadingBisB156/94mmBHGBandBheBhasBnoBhistoryBofBDM
BorBCKD.BFollowingBcurrentBbestBevidence,ByouBconsiderBaddingBwhichBofBtheBfollowin
gBmedications?
A.BACEI
B.BARBs
C.Bbeta-adrenergicBreceptorBantagonist
D.BcalciumBchannelBblockerB-BAnswerD.BcalciumBchannelBblocker
nondihydropyridineBcalciumBchannelBblockersBareBcontraindicatedBinBptsBwith:
A.BtypeB1BDM
B.BaBhistoryBofBvenousBthromboembolism
C.BsevereBleftBventricularBdysfunction
D.BconcomitantBtreatmentBwithBanBACEIB-BAnswerC.BsevereBleftBventricularBdysfunction
InBobtainingBanBofficeBBPBmeasurement,BwhichBofBtheBfollowingBisBmostBreflectiveBofB
theBbestBpractice?
A.BtheBpatientBshouldBsitBinBaBchairBwithBfeetBflatBonBtheBfloorBforBatBleastB5Bminute
sBbeforeBobtainingBtheBreading
B.BtheBBPBcuffBshouldBnotBcoverBmoreBthanB50%BofBtheBupperBarm
C.BtheBptBshouldBsitBonBtheBedgeBofBtheBexamBtableBw/oBarmBsupportBtoBenhanceBre
adingBaccuracy
D.BobtainingBtheBBPBreadingBimmediatelyBafterBtheBptBwalksBintoBtheBexamBroomBisBr
ecommendedB-
BAnswerA.BtheBpatientBshouldBsitBinBaBchairBwithBfeetBflatBonBtheBfloorBforBatBleastB5
BminutesBbeforeBobtainingBtheBreading